. Author manuscript; available in PMC: 2010 Jun 7.

Published in final edited form as: Cancer Causes Control. 2008 Sep 3;20(1):87–96. doi: 10.1007/s10552-008-9220-z

Table 5.

Adjusted OR (95% CI) for interaction between oral contraceptive use and postmenopausal hormone use and gliomas among postmenopausal women, and self-reporting respondents only in the San Francisco Adult Glioma Study, 1991–2004

Oral contraceptive use among self-reporting women	Never postmenopausal hormone use among self-reporting women		Ever postmenopausal hormone use among self-reporting women

	Case/control	OR^† (95% CI)	Case/control	OR^† (95% CI)
Never	38/69	1.00 (ref)	37/108	0.55 (0.30–0.98)
Ever	32/45	0.83 (0.41–1.69)	47/105	0.50 (0.25–0.98)

Oral contraceptive use among all women	Never postmenopausal hormone use among all women		Ever postmenopausal hormone use among all women

	Case/control	OR^† (95% CI)	Case/control	OR^† (95% CI)

Never	102/70	1.00 (ref)	84/108	0.57 (0.37–0.88)
Ever	45/45	0.60 (0.33–1.10)	61/106	0.36 (0.20–0.64)

^†

adjusted for frequency matched factors age (restricted quadratic splines), ethnicity and education